The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Fulbert, Kano, Jessica, Ma, Julia, Guindy, Mera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946878/
https://www.ncbi.nlm.nih.gov/pubmed/35323345
http://dx.doi.org/10.3390/curroncol29030145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946878/
https://www.ncbi.nlm.nih.gov/pubmed/35323345
http://dx.doi.org/10.3390/curroncol29030145

Ejemplares similares